Columbia Solid Tumor (CSTP) Subpanels

 

Purpose: Detects commonly mutated genes in the following disease classes; Lung, Colorectal/Pancreatic, Cholangiocarcinoma, GIST, Histiocytic, Melanoma, Urothelial, and Thyroid
CPT Codes: 81445, 81479, 88381
Methodology: Next Generation Sequencing (NGS) of DNA
Turnaround Time: 14 days; 12 days for Lung Panel
Specimens Accepted: Formalin-fixed paraffin embedded (FFPE) or frozen tissue, Cytology specimens in CytoLyt solution, whole blood or bone marrow in EDTA, or DNA extracted from a CLIA laboratory
Available Subpanels:

Lung Panel: BRAF(NM_004333 e11,15); EGFR(NM_005228 e3,7,12,15,18-21); ERBB2(NM_004448 e8,17,19-21); KRAS(NM_004985 e2-4); MET(NM_001127500 e2,14,16,18,19); PIK3CA(NM_006218 e2,3,5,7,8,10,14,19,21), POLD1(NM_002691 e4-10,15-20,24), POLE(NM_006231 e1,2,9,11,13,14,20,21,25,26); STK11(NM_000455 e1-9, full coding sequence)

Colorectal/Pancreatic Panel: BRAF(NM_004333 e11,15), KRAS(NM_004985 e2-4), NRAS(NM_002524 e2-4), PIK3CA(NM_006218 e2,3,5,7,8,10,14,19,21), POLD1(NM_002691 e4-10,15-20,24), POLE(NM_006231 e1,2,9,11,13,14,20,21,25,26), STK11(NM_000455e1-9, full coding sequence)          

Cholangiocarcinoma Panel: BRAF(NM_004333 e11,15), FGFR2(NM_000141 e7,9,12), IDH1(NM_005896 e4), IDH2(NM_002168 e4), KRAS(NM_004985 e2-4), NRAS(NM_002524 e2-4), POLD1(NM_002691 e4-10,15-20,24), POLE(NM_006231 e1,2,9,11,13,14,20,21,25,26)

GIST Panel: KIT(NM_000222 e8,9,10,11,13,14,15,17,18), PDGFRA(NM_006206 e12,14,15,18)

Histiocytic Panel: ARAF(NM_001654 e7), BRAF(NM_004333 e11,15, KRAS(NM_004985 e2-4), MAP2K1(NM_002755 e2,3,6,7,11), NRAS(NM_002524 e2-4), PIK3CA(NM_006218 e2,3,5,7,8,10,14,19,21)

Melanoma Panel: BRAF(NM_004333 e11,15), CYSLTR2(NM_001308465 e5), EIF1AX(NM_001412 e1,2,6), GNAQ(NM_002072 e2,4,5), GNA11(NM_002067 e4-5), IDH1(NM_005896 e4), KIT(NM_000222 e8,9,10,11,13,14,15,17,18), KRAS(NM_004985 e2-4), NRAS(NM_002524 e2-4), PLCB4(NM_000933 e20), RAC1(NM_006908 e2), SF3B1(NM_012433 e14), SRSF2(NM_003016 e1), TERT(promoter, NM_198253 5’UTR)

Urothelial Panel: AKT1(NM_005163 e3), CDKN2A(NM_000077 e2), FGFR1(NM_023110 e4,7,12,14), FGFR2(NM_000141 e7,9,12), FGFR3(NM_000142 e7,9,14,16,18), HRAS(NM_005343 e2-4), KRAS(NM_004985 e2-4), NRAS(NM_002524 e2-4), PIK3CA(NM_006218 e2,3,5,7,8,10,14,19,21), TERT(promoter, NM_198253 5’UTR), TP53(NM_000546 e2,4-10),

Thyroid Panel: AKT1(NM_005163 e3), BRAF(NM_004333 e11,15), CTNNB1(NM_001904 e3,7,8), EIF1AX(NM_001412 e1,2,6), GNAS(NM_000516 e8,9), HRAS(NM_005343 e2-4), KRAS(NM_004985 e2-4), NRAS(NM_002524 e2-4), PIK3CA(NM_006218 e2,3,5,7,8,10,14,19,21), PTEN(NM_000314 e1-9), RET(NM_020975 e10,11,13,15,16), TERT(promoter, NM_198253 5’UTR), TP53(NM_000546 e2,4-10), TSHR(NM_000369 e9-10)  

Forms: 1. PGM Oncology Requisition
2. Insurance Pre-Authorization Form
3. Medicare Advance Beneficiary Notice Form
4. CCCP Letter of Medical Necessity Template